Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study by Rauch, A et al.
HIV/AIDS • CID 2006:43 (1 July) • 99
H I V / A I D SB R I E F R E P O R T
Prospective Genetic Screening
Decreases the Incidence of Abacavir
Hypersensitivity Reactions
in the Western Australian HIV
Cohort Study
A. Rauch,1,2 D. Nolan,1 A. Martin,1 E. McKinnon,1 C. Almeida,1
and Simon Mallal1
1Centre for Clinical Immunology and Biomedical Statistics, Perth, Australia;
and 2Division of Infectious Diseases, University Hospital Berne, Switzerland
(See the editorial commentary by Phillips on pages 103–5)
Abacavir therapy is associated with significant drug hyper-
sensitivity in ∼8% of recipients, with retrospective studies
indicating a strong genetic association with the HLA-B*5701
allelle. In this prospective study, involving 260 abacavir-naive
individuals (7.7% of whom were positive for HLA-B*5701),
we confirm the usefulness of genetic risk stratification, with
no cases of abacavir hypersensitivity among 148 HLA-B*5701–
negative recipients.
Abacavir drug hypersensitivity represents an idiosyncratic, mul-
tisystem inflammatory reaction that occurs in 5%–8% of white
patients initiating this commonly prescribed HIV drug [1, 2].
Clinical symptoms appear in 190% of cases within 6 weeks of
commencing abacavir treatment [1] and include fever, rash,
gastrointestinal symptoms, and lethargy or malaise. A history
of definite abacavir hypersensitivity precludes any further use
of abacavir, because rechallenge can evoke severe and poten-
tially life-threatening reactions.
Clinical risk factors associated with abacavir hypersensitivity
have been described, with relative protection associated with
African racial origin, male sex, and more-advanced HIV disease
stage in a meta-analysis of 18000 subjects in 34 clinical trials
[2]. Higher CD8+ T cell count at the time of initiating abacavir
treatment has also been associated with abacavir hypersensi-
tivity [3]. However, genetic susceptibility conferred by the pres-
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ence of a specific HLA allele—HLA-B*5701—appears to rep-
resent the dominant risk factor for abacavir hypersensitivity
[4–8]. The frequency distribution of this genetic marker in
different populations is likely to provide a rational basis for
racially defined differences in susceptibility [7, 9], whereas the
critical role of HLA-B*5701 in generating and directing CD8+
T cell–dependent, HLA-restricted immune responses suggests
a key role for this genetic variant in the pathogenesis of an
abacavir-specific immune response [6, 8].
Following the recognition of a strong predictive associa-
tion between HLA-B*5701 carriage and abacavir hypersensitiv-
ity in our study population in 2001, a prospective testing strat-
egy was commenced on the basis that HLA-B*5701 testing could
sharply discriminate individual risk of developing abacavir hy-
persensitivity into low-risk (!1%) and high-risk (170%) groups
[4]. Abacavir prescription was therefore avoided in HLA-
B*5701–positive patients in the Western Australian HIV cohort
from 2002 onwards. Here, we describe a single-center cohort
study involving all abacavir-naive individuals starting or chang-
ing antiretroviral therapy (ART) during a study period from
January 2002 through July 2005 (a total of 260 subjects). The
study included 121 initial ART prescriptions and 214 nucleo-
side reverse-transcriptase inhibitor (NRTI) treatment changes
among 178 abacavir-naive patients (39 of whom where also
considered in the analysis of ART-naive patients). As a com-
ponent of routine clinical care, high-resolution HLA class I and
class II typing (HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-
DQ) was undertaken for all subjects by direct DNA sequencing,
as described elsewhere [4, 6]. Diagnostic classification of aba-
cavir hypersensitivity reactions in this study population was
performed using standardized clinical criteria [1, 2, 4, 6]. There-
fore, a diagnosis of abacavir hypersensitivity required the pres-
ence of at least 2 symptoms of fever, rash, nausea, vomiting,
headache, respiratory and gastrointestinal symptoms, lethargy,
myalgia, or arthralgia, occurring !6 weeks after initial abacavir
exposure. Patients stopping abacavir therapy within 6 weeks
after initiation because of symptoms that did not meet the
diagnostic criteria for abacavir hypersensitivity were also as-
sessed. Adjunctive epicutaneous patch testing [8] was per-
formed in all suspected cases of abacavir hypersensitivity and
in unclear cases for which patients provided consent. All cases
in which abacavir treatment was discontinued within 6 weeks
after commencing therapy with the drug were examined, both
in the prospective study period (January 2002 through July
2005) and in the period before the introduction of pharma-
cogenetic screening (January 1998 through December 2001).
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Table 1. Characteristics of abacavir-naive, HIV-infected patients commencing or changing antiretroviral therapy.
Patient characteristics
Treatment-naive group Treatment-experienced groupa
Started
abacavir therapy
(n p 43)
Did not start
abacavir therapy
(n p 78) P
Started
abacavir therapyb
(n p 92)
Did not start
abacavir therapy
(n p 86) P
Sex
Male 36 (83) 57 (73) 72 (78) 70 (81)
Female 7 (16) 21 (27) .3 20 (22) 16 (19) .7
Age, median years (IQR) 43 (36–49) 39 (30–46) .1 41 (35–51) 41 (33–50) .4
Ethnicity
White 32 (74) 57 (73) 70 (76) 66 (77)
Aboriginal 3 (7) 7 (9) 8 (9) 8 (9)
African 4 (9) 4 (5) 7 (8) 3 (3)
Asian 4 (9) 10 (13) .8 7 (8) 9 (10) .6
Route of HIV infection
MSM 19 (44) 31 (40) 51 (55) 41 (47)
Other 24 (56) 47 (60) .7 41 (44) 45 (52) .3
Immunological status
CD4+ cell count, median cells/mL (IQR) 352 (240–464) 285 (84–420) .03 479 (253–726) 287 (96–442) !.001
CD8+ cell count, median cells/ml (IQR) 948 (633–1403) 762 (470–1160) .06 884 (644–1255) 837 (539–1159) .2
HIV RNA loadc
!50 copies/mL NA NA 50 (54) 24 (28)
50–105 copies/mL 30 (73) 23 (32) 33 (36) 30 (35)
1105 copies/mL 11 (27) 49 (68) !.001 9 (10) 32 (37) !.001
CDC stage
Prior CDC stage C event 2 (5) 13 (17) 14 (15) 25 (29)
No prior CDC stage C event 41 (95) 65 (83) .08 78 (85) 61 (70) .03
HLA-B*5701 status
Positive 1 (2) 8 (10) 2 (2) 12 (14)
Negative 42 (97) 70 (89) .15 90 (98)b 74 (86) .004
NOTE. Data are no. (%) of patients, unless otherwise indicated. Data are for time of commencing antiretroviral therapy or at time of first treatment change.
Characteristics at the time of commencing or changing antiretroviral therapy were compared by use of x2 and Mann-Whitney U tests. CDC, Centers for Disease
Control and Prevention; IQR, interquartile range; MSM, men who have sex with men; NA, not available.
a Includes 39 patients considered in the treatment-naive analysis who did not start abacavir therapy as part of the first course of antiretroviral therapy.
b An additional 16 HLA-B*5701–negative patients started abacavir subsequently (i.e., for their second or third change in antiretroviral therapy).
c Information on HIV load was not available at this time point for 8 (6%) of 121 abacavir-naive patients.
As shown in table 1, patients starting abacavir therapy did
not differ significantly from those starting therapy with alter-
native antiretroviral drugs with respect to sex, age, ethnicity,
and route of HIV infection. Patients not commencing abacavir
therapy had more-advanced HIV disease (i.e., significantly
higher HIV loads, lower CD4+ cell counts, and more-frequent
AIDS-defining events), compared with patients starting aba-
cavir therapy, reflecting the limited use of abacavir for patients
with more-advanced HIV disease during the 2002–2005 study
period, when abacavir was frequently incorporated into triple-
NRTI regimens (i.e., zidovudine-lamivudine-abacavir therapy).
Overall patterns of NRTI drug prescription are presented in
table 2.
Among 121 treatment-naive patients initiating first-line HIV
therapy, 112 (92.6%) were found to be negative for the HLA-
B*5701 allele, of whom 42 (37.5%) started abacavir therapy
(tables 1 and 2). In 2 of these cases, abacavir was discontinued
within 6 weeks after initiation because of symptoms that were
not consistent with drug hypersensitivity (diarrhea in 1 patient
and headache probably related to concurrent zidovudine treat-
ment in 1 patient). Of the 9 ART-naive, HLA-B*5701–positive
patients identified by genetic screening, 1 patient started aba-
cavir treatment before the review of HLA results. This 48-year-
old white man subsequently developed a typical abacavir hy-
persensitivity reaction, characterized by the development of a
widespread maculopapular rash, fever, and constitutional symp-
toms 6 days after commencing abacavir therapy. Treatment was
discontinued 2 days later, with resolution of symptoms within
24 h after discontinuation of therapy. A positive epicutaneous
patch test result was subsequently recorded with vesicular, eryth-
ematous skin changes following application of both 1% and 10%
abacavir concentrations in a petrolatum vehicle.
During this study period, 178 ART-experienced but abacavir-
naive patients switched NRTI therapy. From this group, 164
(92.1%) were identified as HLA-B*5701–negative patients. Aba-
cavir was prescribed for 106 (64.6%) of these individuals; 90
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Table 2. Choice of nucleoside reverse-transcriptase inhibitor (NRTI) therapy in abacavir-naive patients.
NRTI
No. (%) of patients
Treatment-naive group Treatment-experienced groupa
HLA-B*5701–negative
patients
(n p 112)
HLA-B*5701–positive
patients
(n p 9)
HLA-B*5701–negative
patients
(n p 164)
HLA-B*5701–positive
patients
(n p 14)
Abacavirb 42 (37) 1 (11) 90 (55) 2 (14)
Zidovudine 70 (62) 6 (66) 45 (27) 5 (36)
Lamivudine 109 (97) 8 (89) 63 (38) 5 (36)
Stavudine 3 (3) 1 (11) 5 (3) 1 (7)
Didanosine 2 (2) 1 (11) 7 (4) 2 (14)
Tenofovir 14 (12) 2 (22) 34 (20) 6 (43)
a First treatment change.
b Abacavir-lamivudine-zidovudine (Trizivir; GlaxoSmithKline) accounts for 16 (37%) of 43 abacavir prescriptions in treatment-naivepatients
and 38 (41%) of 92 abacavir prescriptions in patients receiving second-line HIV therapy. Overall, 48 (89%) of 54 of abacavir-lamivudine-
zidovudine prescriptions were for patients with a CD4+ cell count 1200 cells/mL, and 51 (94%) of 54 prescriptions were for patients with
an HIV RNA level !105 copies/mL.
Figure 1. Proportion of patients stopping abacavir therapy in the first
6 weeks of treatment before and after introduction of prospective genetic
screening. The numbers below the time periods indicate the number of
abacavir-naive individuals starting abacavir therapy. The upper line ()
indicates the proportion of patients who stopped abacavir therapy because
of any symptoms in the first 6 weeks of therapy; the number of patients
indicated below the circle indicates the total number of patients with
“minor” symptoms (abacavir hypersensitivity not excluded) plus the num-
ber of patients with definitive abacavir hypersensitivity reactions. The
bottom line () indicates the proportion of patients with definitive aba-
cavir hypersensitivity reactions; the number of patients in the respective
time period is indicated below the diamonds.
patients started abacavir therapy at the time of their first treat-
ment change (tables 1 and 2), and 16 patients started abacavir
therapy subsequently (at the second or third change in ART).
In 4 cases, abacavir was discontinued within 6 weeks. One
patient developed nonspecific symptoms of headache and cold
sweats that were not responsive to abacavir withdrawal within
1 week after withdrawal of therapy, and 2 patients developed
symptoms of nausea and vomiting attributed to nevirapine
(including rash in 1 patient) that were associated with negative
epicutaneous patch test results. One patient suffered from HIV-
associated dermatosis that was present before starting abacavir
therapy. Of the 14 ART-experienced, HLA-B*5701–positive pa-
tients who were screened, 2 started abacavir therapy. In 1 case,
HLA test results were not reviewed before drug prescription,
and 1 patient made an informed choice to initiate abacavir
therapy because HLA typing demonstrated the absence of HLA-
B57–associated ancestral haplotype markers in central and class
II major histocompatibility complex regions (i.e., C4A6 and
HLA-DR7/HLA-DQ3). This patient also had limited treatment
options because of previous treatment complications (e.g., se-
vere lipoatrophy). Both of these white patients experienced
abacavir hypersensitivity reactions, confirmed with epicutane-
ous patch test results that were strongly positive to 1% and
10% abacavir concentrations.
Overall, the incidence of abacavir hypersensitivity in this
prospectively screened population was 3 (2.0%) of 151 patients,
with no cases diagnosed among the 148 HLA-B*5701–negative
patients who received abacavir treatment. Therefore, the inci-
dence of abacavir hypersensitivity decreased significantly (P
p .01, by Fisher’s exact test), compared with the 8% prevalence
of abacavir hypersensitivity before genetic screening (figure 1),
a result that was consistent with published data in predomi-
nantly white patient cohorts [2, 3, 10]. The proportion of pa-
tients stopping abacavir therapy because of symptoms that did
not meet diagnostic criteria for drug hypersensitivity during
the first 6 weeks of therapy also decreased, from 8.5% before
genetic screening to 4.0% after introduction of screening (P
p .1, by Fisher’s exact test) (figure 1). These results, although
reinforcing the positive predictive value of HLA-B*5701 testing
for these patients, also demonstrate that failure to review HLA
results before abacavir prescription can have significant adverse
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consequences. Therefore, a system has now been developed
whereby HLA-B*5701–positive results are routinely noted in the
allergy field of the pharmacy system database, ensuring that aba-
cavir is not dispensed to HLA-B*5701–positive patients without
prior explicit knowledge and consent of the treating clinician.
The prevalence of HLA-B*5701 carriage in this population
was 20 (7.7%) of 260 patients, all of whom were identified as
white, which is consistent with expected results from popula-
tion-based HLA data. It is also notable that high-resolution
HLA typing methods used in this study were able to discrim-
inate the HLA-B*5701 allele from closely related alleles, such
as HLA-B*5702 (in 2 cases), HLA-B*5703 (in 1 case), and HLA-
B*5801/5802 (in 9 cases). Subjects with these HLA alleles were
prescribed abacavir (including 2 subjects with HLA-B*5702, 1
subject with HLA-B*5703, and 3 subjects with HLA-B*5801)
without incident, indicating that susceptibility is mapped spe-
cifically to the HLA-B*5701 allele and its related major histo-
compatibility complex haplotype.
We, therefore, conclude that prospective genetic screening
with avoidance of abacavir prescription in patients carrying the
susceptibility marker HLA-B*5701 has had a dramatic impact
on the incidence of abacavir hypersensitivity in the Western
Australian HIV Cohort. We acknowledge that assessing the
broader clinical implications of this approach to abacavir pre-
scribing in racially diverse HIV-infected populations requires
further study, which may be conducted in light of the expected
frequency distribution of HLA-B*5701 and its associated major
histocompatibility complex haplotype in these population
groups [9]. However, given the otherwise favorable safety pro-
file of abacavir once drug hypersensitivity is excluded [11], this
pharmacogenomic approach to risk stratification would appear
to pave the way for more confident abacavir prescription.
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